Cascading supply disruptions: From transdermal shortages to injectable depletion
The deficit in American estrogen distribution has reached an acute inflection point as prolonged shortages of estradiol transdermal patches generate a systemic domino effect across substitute modalities. Women unable to fulfill standard patch prescriptions have increasingly turned to alternative hormone therapy products, including vaginal creams and intramuscular injections.
This rapid, uncoordinated demand migration has overwhelmed secondary manufacturing tiers. The American Society of Health-System Pharmacists (ASHP) recently designated multiple estradiol injection formulations produced by Hikma, American Regent, and Par Sterile Products as actively in shortage, while vaginal estradiol creams from Viatris, Padagis, and Teva have been placed on strict allocation or backorder status.
Shortages expand from transdermal skin patches into critical injectable solutions and topical vaginal estradiol creams.
Major pharmaceutical suppliers including Hikma, Teva, Viatris, and Padagis place core hormone therapies under strict allocation controls.
*"Persistent patch shortages have been going on for a while and as prescribers and their patients go to alternative gels and creams, there has been a domino effect impacting the supplies of these prescriptions as well." — Kathleen Jordan*
















